Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 β-lactamase confers increased MIC of cefepime

被引:38
作者
Vakulenko, SB
Golemi, D
Geryk, B
Suvorov, M
Knox, JR
Mobashery, S
Lerner, SA
机构
[1] Wayne State Univ, Dept Med, Detroit, MI 48201 USA
[2] Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48201 USA
[3] Wayne State Univ, Inst Drug Design, Detroit, MI 48201 USA
[4] Wayne State Univ, Dept Chem, Detroit, MI 48202 USA
[5] Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA
关键词
D O I
10.1128/AAC.46.6.1966-1970.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The class C beta-lactamase from Enterobacter cloacae P99 confers resistance to a wide range of broad-spectrum beta-lactams but not to the newer cephalosporin cefepime. Using PCR mutagenesis of the E. cloacae P99 ampC gene, we obtained a Leu-293-Pro mutant of the P99 beta-lactamase conferring a higher MIC of cefepime (MIC, 8 mug/ml, compared with 0.5 mug/ml conferred by the wild-type enzyme). In addition, the mutant enzyme produced higher resistance to ceftazidime but not to the other beta-lactams tested. Mutants with 15 other replacements of Leu-293 were prepared by site-directed random mutagenesis. None of these mutant enzymes conferred MICs of cefepime higher than that conferred by Leu-293-Pro. We determined the kinetic parameters of the purified E. cloacae P99 beta-lactamase and the Leu-293-Pro mutant enzyme. The catalytic efficiencies (k(cat)/K-m) of the Leu-293-Pro mutant beta-lactamase for cefepime and ceftazidime were increased relative to the respective catalytic efficiencies of the wild-type P99 beta-lactamase. These differences likely contribute to the higher MICs of cefepime and ceftazidime conferred by this mutant beta-lactamase.
引用
收藏
页码:1966 / 1970
页数:5
相关论文
共 30 条
[1]   Salmonella enteritidis:: AmpC plasmid-mediated inducible β-lactamase (DHA-1) with an ampR gene from Morganella morganii [J].
Barnaud, G ;
Arlet, G ;
Verdet, C ;
Gaillot, O ;
Lagrange, PH ;
Philippon, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2352-2358
[2]  
Barnaud G, 2001, FEMS MICROBIOL LETT, V195, P185, DOI 10.1111/j.1574-6968.2001.tb10519.x
[3]   Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance [J].
Bauernfeind, A ;
Stemplinger, I ;
Jungwirth, R ;
Giamarellou, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (01) :221-224
[4]   A novel type of AmpC β-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia [J].
Bauernfeind, A ;
Schneider, I ;
Jungwirth, R ;
Sahly, H ;
Ullmann, U .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1924-1931
[5]   Plasmid-encoded AmpC β-lactamases:: How far have we gone 10 years after the discovery? [J].
Bauernfeind, A ;
Chong, Y ;
Lee, K .
YONSEI MEDICAL JOURNAL, 1998, 39 (06) :520-525
[6]   REEVALUATION OF THE FACTORS INVOLVED IN THE EFFICACY OF NEW BETA-LACTAMS AGAINST ENTEROBACTER-CLOACAE [J].
BELLIDO, F ;
PECHERE, JC ;
HANCOCK, REW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (01) :73-78
[7]   Molecular characterization of FOX-4, a new ampC-type plasmid-mediated β-lactamase from an Escherichia coli strain isolated in Spain [J].
Bou, G ;
Oliver, A ;
Ojeda, M ;
Monzón, C ;
Martínez-Beltrán, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2549-2553
[8]  
Bush K, 1998, ADV EXP MED BIOL, V456, P71
[9]   RESISTANCE CAUSED BY DECREASED PENETRATION OF BETA-LACTAM ANTIBIOTICS INTO ENTEROBACTER-CLOACAE [J].
BUSH, K ;
TANAKA, SK ;
BONNER, DP ;
SYKES, RB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (04) :555-560
[10]   CEFEPIME [J].
CUNHA, BA ;
GILL, MV .
MEDICAL CLINICS OF NORTH AMERICA, 1995, 79 (04) :721-732